Everest Medicines 2025: NMPA Approves IND for Cancer Vaccine EVM14
Everest Medicines, a biopharmaceutical company, announced that the Investigational New Drug (IND) application for EVM14, a Tumor-Associated Antigen (TAA) cancer vaccine, has been approved by the National Medical Products Administration (NMPA) in China.
This milestone marks a key step in the Company's efforts to develop innovative mRNA therapeutics in oncology. EVM14 is Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receive IND approvals from both China's NMPA and the U.S. Food and Drug Administration (FDA).
EVM14 is an off-the-shelf therapeutic mRNA cancer vaccine developed based on Everest Medicines' proprietary mRNA platform. First-in-human trials are expected to start in Q1 2026.
No additional quotes available.
Author's summary: Everest Medicines' EVM14 cancer vaccine gets NMPA approval.
More News
- Class Action Alleges Microsoft Choked AI Supply to Lift ChatGPT Costs - Decrypt
- Alec Baldwin reassures fans after crashing car into ‘big fat tree’
- Pacific Northwest seasonal farmworkers to earn less following Trump administration policy change
- Cheryl's shock call to Liam Payne's girlfriend
- 'Helicopters may soon be banned from cruise ships in Antarctica', warns Polar Latitude Expeditions boss
- NYT Connections Hints Today, October 14, 2025: See Today’s Word List And Helpful Clues | Herzindagi
- Sydney to Auckland Ocean Race Day 4 - Lucky claims line honours but race still on
- Nuno Espirito Santo has finetuned new tactical plan during international break that will guarantee West Ham survival
- A Conference of Metamorphosis — Art+ Magazine
- Commentary: UK opens ISAs to crypto – is it too little, too late? | University of Surrey